According to the World Health Organization, the prevalence of obesity nearly tripled between 1975 and 2016, and since the first known case of COVID-19 in December 2019 through May 23, 2021, there have been 167 million cases reported worldwide, and more than 3.4 million deaths. Obesity is a risk factor for adverse outcomes in COVID-19, tripling the risk of hospitalization and also increasing the risk for mechanical ventilation and death. This has led to obesity and COVID-19 being considered a syndic, or synergistic epidemic, which is when two or more epidemics interact synergistically. The result of their interaction contributes to excess disease burden in a population. Due to social determinants of health including racial and ethnic discrimination, access to healthy food and health care, location and physical environment, socioeconomic status, education, and social and community context, there are many common underpinnings between obesity, chronic diseases, and COVID-19.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Novo Nordisk Inc.
Primary care physicians, endocrinologists, nurse practitioners, PAs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kushner reports that he receives research support from Epitomee Medical. He is a consultant for Novo Nordisk and WW International, Inc.
Dr. Ryan reports that she is on the speakers bureau for Novo Nordisk. She is a consultant for Alyvant, Inc.; Boeringer Ingelheim; Epitomee; Gila Therapeutics, Inc.; IFA Celtic; Janssen Pharmaceuticals, Inc.; Naturally Slim; Novo Nordisk; Phenomix Sciences; Real Appeal (United Health); ReDesign Health Inc.; Roman; and Sanofi. She has ownership interest in Epitomee; Gila Therapeutics, Inc.; Phenomix Sciences; ReDesign Health Inc.; Scientific Intake; and Xeno Biosciences Inc.
Michael J. Franks, MSN, AGACNP-BC, FNP, BC (planning committee) has no disclosures to report.
Warren Beckman (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-128-H01-P.
Call us at 877.CME.PROS (877.263.7767).